2,6-dioxo-hexanoic acid ethyl ester | 98559-00-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,6-dioxo-hexanoic acid ethyl ester
• 英文别名: 2,6-Dioxo-hexansaeure-aethylester；Ethyl 2,6-dioxohexanoate；ethyl 2,6-dioxohexanoate
• CAS: 98559-00-3
• 化学式: C₈H₁₂O₄
• 分子量: 172.181
• InChiKey: ISGSDUPWNBWZPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,6-dioxo-hexanoic acid ethyl ester 生成 2,6-disemicarbazono-hexanoic acid ethyl ester
  参考文献：
  名称：

  5-formyl-2-oxovaleric acid, its salts and esters and a process of producing the same

  摘要：

  公开号：

  US02891988A1
• 作为产物：
  描述：

  1-环戊烯-1-甲酸乙酯 在 氧气 、 臭氧 、 溶剂黄146 作用下， 生成 2,6-dioxo-hexanoic acid ethyl ester 、 2-hydroxy-6-oxo-tetrahydro-pyran-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  5-formyl-2-oxovaleric acid, its salts and esters and a process of producing the same

  摘要：

  公开号：

  US02891988A1

文献信息

• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0330788A1

  公开（公告）日：1989-09-06

  The present invention is directed to the use of heterocyclic esters of hexahydro-8-hydroxy-2,6-methano-2H-­quinolizin-3(4H)-ones and hexahydro-B-hydroxy-2,6-methano-­2H-quinolizines in the manufacture of cardiac antiarrhythmic agents

  本发明涉及在制造心脏抗心律失常药物中使用六氢-8-羟基-2,6-甲基-2H-喹诺利啉-3(4H)-酮和六氢-B-羟基-2,6-甲基-2H-喹诺利啉的杂环酯。
• Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0329903A1

  公开（公告）日：1989-08-30

  The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-­ones and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of ocular hypotensive agents.

  本发明涉及六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的酯类在制造降眼压剂中的应用。
• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0329904A1

  公开（公告）日：1989-08-30

  The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-­ones and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of anxiolytic agents.

  本发明涉及六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的酯类在抗焦虑剂生产中的应用。
• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0329905A1

  公开（公告）日：1989-08-30

  The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-­ones and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of gastric motility stimulants.

  本发明涉及六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的酯类在胃动力兴奋剂生产中的应用。
• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0329932A2

  公开（公告）日：1989-08-30

  The present invention relates to the use of quinolizine and quinolizinone derivatives in the manufacture of a medicament for the treatment of anxiety, psychosis, glaucoma, and to stimulate gastric motility. The invention also relates to certain novel derivatives of quinolizine and quinolizinone which are useful for the purposes indicated above and which are also useful for the treatment of migraine and the treatment of nausea and vomiting.

  本发明涉及使用喹嗪和喹嗪酮衍生物制造治疗焦虑症、精神病、青光眼和刺激胃肠蠕动的药物。本发明还涉及喹嗪和喹嗪酮的某些新型衍生物，这些衍生物可用于上述目的，也可用于治疗偏头痛和治疗恶心呕吐。